Osteonecrosis of jaws related to intravenous bisphosphonates: The experience of a Jordanian teaching hospital

Annals of the Royal College of Surgeons of England

Volumn 92, Issue 6, 2010, Pages 489-494

  Baqain, Zaid H ^a   Sawair, Faleh A ^a   Tamimi, Zaid ^a   Bsoul, Nazzal ^a   Al Edwan, Ghazi ^a   Almasad, Jamal K ^a   Abbadi, Abdalla A ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Bisphosphonates; Chemotherapy; Osteonecrosis of jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE; AGED; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; FEMALE; HEALTH; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MALE; MIDDLE AGED; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; ORAL HEALTH; OSTEONECROSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957898500     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588410X12699663903395     Document Type: Article

References (19)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
2. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-41
3. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 186-93.
4. Van Beek ER, Löwik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002; 30: 64-70.
5. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Invest 2010; 14: 35-41.
6. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-6.
7. Chaudhry AN, Ruggiero SL. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofac Surg Clin North Am 2007; 19: 199-206.
8. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65:1328-31.
9. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003; 19: 395-414.
10. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al.; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. The role of bisphosphonates in multiple myeloma. J Clin Oncol 2003; 21: 3177-8.
11. Hohnecker JA. Novartis 'Dear Doctor' precautions added to label of Aredia and Zometa. 24 September 2004.
12. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-76.
13. McLeod NM, Davies BJ, Brennan PA. Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. Br Dent J 2007; 203: 641-4.
14. Migliorati CA, Casiglia J, Epstein J, Siegel, MA, Woo SB. Managing the care patients with bisphosphonate-associated osteonecrosis. JADA 2005; 136:1658-68.
15. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B.; American Association of Oral and Maxillofacial Surgeons. American Associationof Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009; 67 (Suppl): 2-12.
16. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
17. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21: 1545-8.
18. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral MaxillofacSurg 2008; 66: 625-31.
19. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genomewide single nucleotide polymorphism analysis. Blood 2008; 112: 2709-12.